Glutamate is an amino acid and a key neurotransmitter in the central nervous system. It acts as an excitatory neurotransmitter, involved in signaling between nerve cells. Glutamate functions by binding to specific receptors, such as NMDA receptors and AMPA receptors, and mediating synaptic transmission and neuronal communication. Glutamate has diverse roles in various physiological processes, including learning, memory, and synaptic plasticity. In terms of disease indications, glutamate dysregulation has been implicated in neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke. Modulating glutamate levels and its receptors are important therapeutic targets in the management of these conditions. According to the World Health Organization (WHO), Alzheimer's disease is a major global health challenge, affecting an estimated 50 million people worldwide, with Europe and the United States having high prevalence rates. In Europe, the number of people with Alzheimer's disease is projected to double by 2050. Parkinson's disease affects approximately 1% of the European population aged 60 years and above, and in the United States, around 1 million individuals are living with the disease. Epilepsy is also a prevalent neurological disorder, with over 6 million people in Europe and 3.4 million people in the United States affected by the condition. Stroke, a leading cause of disability and death globally, affects millions of individuals each year.
The growth drivers of the glutamate market include the increasing prevalence of neurological disorders, advancements in diagnostic techniques, and the development of novel drugs targeting glutamate pathways. Companies such as Biohaven, Galderma, AbbVie, Medytox, MeiraGTx, AstraZeneca, Aptinyx, Eirion, Addex, Huons, Synchroneuron, Eli Lilly, MetVital, Ipsen, ATGC Co, Hugel, Novartis, CleveXel Pharma, Daiichi Sankyo, Sage Therapeutics, Camino Pharma, Italfarmaco, Chong Kun Dang, Intra-Cellular Therapies, Saniona, Tonix cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is one such company that is currently conducting a clinical trial of the drug Omipalisib AZD2516 for the treatment of idiopathic pulmonary fibrosis.
Glutamate Market Key Developments:
- In May 2023, Biohaven Pharmaceuticals got preregistration for Troriluzole in spinocerebellar degeneration in the USA
- In May 2023, AbbVie completed a phase-I trial of Botulinum toxin E in Glabellar lines in the USA (IM)
Approved Glutamate Molecules
- Botox (onabotulinumtoxin A)
- Topiramate
- Isoflurane
- Riluzole
- Qsymia (topiramate, phentermine)
- Medytoxin (botulinum toxin type A)
- Evosyal (prabotulinumtoxin A)
- Campral EC (acamprosate delayed release)
- Myobloc (rimabotulinumtoxin B)
- Diamyd (recombinant 65 kDa isoform of human glutamic acid decarboxylase)
- Botulax (botulinum toxin type A)
- Innotox (nivobotulinumtoxinA)
- Stavzor (valproic acid oral)
- AAV-GAD gene therapy
- Coretox (botulinum toxin type A)
- Liztox (botulinum toxin type A)
- Eutox (botulinum toxin type A)
- Exservan (riluzole oral soluble film)
- Anhydrous enol-oxaloacetate (AEO)
- Teglutik (riluzole oral suspension)
Glutamate Pipeline Molecules
- Troriluzole (BHV-4157)
- Botulinum toxin E (AGN-151586)
- relabotulinumtoxina (QM1114)
- Botulinum toxin A (MBA-P01)
- AZD2516
- NYX-2925
- Botulinum toxin A topical (ET-01)
- Raseglurant (ADX-10059)
- NYX-783
- Acamprosate controlled-release (SNC-102)
- KLS-2031
- LY545694
- Botulinum toxin A longer acting (IPN10200)
- Botulinum toxin type A (ATGC-110)
- botulinum toxin type A (HG-102)
- Clostridium botulinum neurotoxin serotype A recombinant (IPN59011)
- CAD-9303
- CVXL-0107
- DS-1150b
- NYX-458
- SAGE-904
- SBP 0069330
- Botulinum toxin A injection (AI-09)
- Liquid botulinum toxin (CKDB-501B)
- Long-acting lumateperone (ITI-007 LAI)
- Ordopidine (ACR 325)
- Tianeptine hemioxalate extended-release (TNX-601 ER)
Clinical Activity and Development of Glutamate
In the Glutamate space, more than 15 companies are conducting around 150 clinical trials in this category of drugs. For instance,
- In May 2023, Allergan completed a phase III trial of Botulinum toxin E in Glabellar lines in the USA, Canada, Germany, Hungary, and Poland (IM)
- In Feb 2023, Q-Med AB initiated a phase III trial of Relabotulinumtoxin A for Facial wrinkles in the USA (IM, injection)
|
Product Name |
Total Studies |
|
Troriluzole (BHV-4157) |
12 |
|
Botulinum toxin E (AGN-151586) |
7 |
|
relabotulinumtoxina (QM1114) |
7 |
|
Botulinum toxin A (MBA-P01) |
6 |
|
AZD2516 |
5 |
|
NYX-2925 |
5 |
|
Botulinum toxin A topical (ET-01) |
5 |
|
Raseglurant (ADX-10059) |
5 |
|
NYX-783 |
3 |
|
Acamprosate controlled-release (SNC-102) |
3 |
|
KLS-2031 |
2 |
|
LY545694 |
2 |
|
Botulinum toxin A longer acting (IPN10200) |
2 |
|
Botulinum toxin type A (ATGC-110) |
2 |
|
Botulinum toxin type A (HG-102) |
2 |
|
Clostridium botulinum neurotoxin serotype A recombinant (IPN59011) |
2 |
|
CAD-9303 |
1 |
|
CVXL-0107 |
1 |
|
DS-1150b |
1 |
|
NYX-458 |
1 |
Target Indication Analysis of Glutamate
Glutamate is targeted as a potential therapeutic intervention for various indications related to neurological disorders. It plays a crucial role in the pathophysiology of conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke. In Alzheimer's disease, the dysregulation of glutamate receptors and excitotoxicity contribute to neuronal damage and cognitive decline. In Parkinson's disease, disrupted glutamate signaling is implicated in motor symptoms and neurodegeneration. Epilepsy involves abnormal glutamate release and receptor activation leading to seizures. Stroke is associated with excessive glutamate release, leading to neuronal excitotoxicity and ischemic damage. Targeting glutamate pathways aims to modulate its levels and receptor activity, potentially offering therapeutic benefits in managing these neurological disorders.
Glutamate Market Regional Analysis
Glutamate Market
The global Glutamate market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US market analysis of glutamate reflects a robust and expanding landscape. Glutamate, as a key neurotransmitter in the central nervous system, plays a critical role in various physiological processes, including cognition and synaptic plasticity. The market for glutamate is driven by several factors, such as the rising prevalence of neurological disorders like Alzheimer's disease, Parkinson's disease, and epilepsy. Moreover, the growing awareness among healthcare professionals and patients about the importance of glutamate in neurological function fuels the demand for effective therapeutic interventions targeting glutamate pathways. Additionally, the increasing focus on research and development activities, advancements in diagnostic techniques, and the development of novel glutamate-modulating drugs contribute to the growth of the market. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for Glutamates. These countries are increasingly adopting Glutamates due to their efficacy and potential to improve patient outcomes. On the other hand, the Glutamate market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the Glutamate market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Glutamate drugs are used in the management of Alzheimer's disease, Parkinson's disease, epilepsy, and stroke.
The growth drivers of the glutamate market include the increasing prevalence of neurological disorders, advancements in diagnostic techniques, and the development of novel drugs targeting glutamate pathways.
The major players in this space are Biohaven, Galderma, AbbVie, Medytox, MeiraGTx, AstraZeneca, Aptinyx, Eirion, Addex, Huons, Synchroneuron, Eli Lilly, MetVital, Ipsen, ATGC Co, Hugel, Novartis, CleveXel Pharma, Daiichi Sankyo, Sage Therapeutics, Camino Pharma, Italfarmaco, Chong Kun Dang, Intra-Cellular Therapies, Saniona, Tonix.
The market for glutamate faces restraints due to challenges associated with targeting and modulating glutamate pathways effectively without disrupting normal physiological functions. Additionally, the complexity of glutamate signaling and its involvement in multiple disease indications pose difficulties in developing specific and selective therapeutic interventions, limiting the growth and adoption of glutamate-targeted treatment.
- Biohaven
- Galderma
- Abbvie
- Medytox
- Meiragtx
- Astrazeneca
- Aptinyx
- Eirion
- Addex
- Huons
- Synchroneuron
- Eli Lilly
- Metvital
- Ipsen
- Atgc Co
- Hugel
- Novartis
- Clevexel Pharma
- Daiichi Sankyo
- Sage Therapeutics
- Camino Pharma
- Italfarmaco
- Chong Kun Dang
- Intra-Cellular Therapies
- Saniona
- Tonix